• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AGN
Click for more information
0.00% 58.5¢

ARGENICA THERAPEUTICS LIMITED - News & Media

Market Cap $71.84M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Argenica Therapeutics Limited is an Australia-based clinical drug development company.... Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Articles & Videos

Argenica Therapeutics dose test raises hopes for stroke victims

Biotech firm Argenica Therapeutics has initiated dosing for the first stroke patient in its Phase 2 clinical trial of ARG007.

28 Mar 2024 12:06 (AEDT)

Argenica shares jump on key designation from US FDA for infant brain injury drug

Argenica Therapeutics announced on Monday the company has won rare pediatric disease designation (RPDD) for its flagship drug ARG-007.

25 Mar 2024 10:55 (AEDT)

Argenica Therapeutics' (ASX:AGN) study delivers "encouraging" results for ARG-007 in treating traumatic brain injury

Argenica Therapeutics (ASX:AGN) has delivered "encouraging" results from a preclinical study assessing the efficiency of ARG-007 in modTBI.

22 Jun 2023 17:06 (AEST)

Argenica Therapeutics (ASX: AGN) taps investors for $4 million to fund ischaemic stroke trial

Argenica Therapeutics (AGN) has wrapped up its $4 million placement to fund the phase two trial of its neurological drug, ARG-007.

02 Jun 2023 15:46 (AEST)

Argenica Therapeutics (ASX:AGN) confirms ARG-007 is well-tolerated in final phase one clinical report

Argenica Therapeutics (ASX:AGN) has confirmed its drug, ARG-007, is safe and well-tolerated its final phase one clinical trial report.

15 May 2023 11:01 (AEST)

Argenica Therapeutics (ASX:AGN) receives $350k cash boost to advance Alzheimers Studies

Argenica Therapeutics (ASX:AGN) has received a non-dilutive $350,000 cash boost to advance its Alzheimer's Disease studies

22 Feb 2023 12:03 (AEDT)

Argenica Therapeutics (ASX:AGN) pre-clinical data points to potential new Alzheimer's treatment

Argenica Therapeutics (ASX:AGN) has reported that pre-clinical data for its flagship ARG-007 product showed the drug inhibited one of the main causes of Alzheimer's Disease.

09 Feb 2023 12:02 (AEDT)

Argenica Therapeutic (ASX:AGN) receives $1.2m grant for traumatic brain injury project

Argenica Therapeutics (ASX:AGN) has been awarded a $1.2 million grant from the Australian Federal Government for traumatic brain injury (TBI) preclinical research.

20 Jan 2023 11:39 (AEDT)



(20min delay)
Last
58.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $71.84M
Open High Low Value Volume
58.5¢ 60.0¢ 57.0¢ $169.5K 294.4K

Buyers (Bids)

No. Vol. Price($)
1 15000 57.5¢
 

Sellers (Offers)

Price($) Vol. No.
59.0¢ 3209 1
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
58.0¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
57.0¢ 60.0¢ 57.0¢ 33870
Last updated 15.56pm 03/05/2024 ?
AGN (ASX) Chart

Top Stories

Sold out signs go up for RIU Resources Roundup in Sydney

More than 115 companies will be participating in this year's RIU Resources Roundup in Sydney.
Infini Resources gearing up for UAV geophys survey over Portland Creek Infini Resources has announced its execution of an application for UAV-based geophysical surveys over its Portland Creek Uranium Project.
Patagonia shares rise above 20% on lithium grades at maiden well in Argentina Patagonia Lithium shares rise above 12 percent on lithium grading nearly 600 parts per million at the first drill well of its Argentinian Formentera Lithium Project.
Car EV-olution accelerates Oz into pole position As the world steers towards a more sustainable future, the surge in electric vehicle (EV) sales is turning industries upside down, and mining is no exception. Australia, famous for its treasure trove of minerals, finds itself right in the middle of this shift, which raises two questions. Firstly,...
Dancing to that same 70s tune, China, and why I'm backing gold It is too early to judge what concrete measures the Future Made in Australia policy will entail. However, any policy which has a stated aim to screen qualifying capital for suitability at a government level, does not seem like a strong signal for foreigners to get on a plane, come visit some mine sites and invest.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.